ValuEngine Upgrades Evogene (NASDAQ:EVGN) to “Buy”

Evogene (NASDAQ:EVGN) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday, ValuEngine reports.

Shares of NASDAQ EVGN remained flat at $$1.45 during midday trading on Thursday. 99 shares of the stock were exchanged, compared to its average volume of 7,761. The firm’s fifty day moving average is $1.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.88 and a quick ratio of 9.88. Evogene has a fifty-two week low of $1.39 and a fifty-two week high of $3.32.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.35). The firm had revenue of $0.19 million for the quarter. Evogene had a negative return on equity of 36.13% and a negative net margin of 1,193.65%.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Meitav Dash Investments Ltd. increased its holdings in shares of Evogene by 44.7% during the 1st quarter. Meitav Dash Investments Ltd. now owns 28,521 shares of the biotechnology company’s stock worth $51,000 after buying an additional 8,804 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Evogene during the 4th quarter worth approximately $71,000. Eidelman Virant Capital acquired a new stake in shares of Evogene during the 2nd quarter worth approximately $102,000. Delek Group Ltd. increased its holdings in shares of Evogene by 4.2% during the 1st quarter. Delek Group Ltd. now owns 217,824 shares of the biotechnology company’s stock worth $397,000 after buying an additional 8,717 shares during the last quarter. Finally, ARK Investment Management LLC increased its holdings in shares of Evogene by 13.7% during the 1st quarter. ARK Investment Management LLC now owns 286,748 shares of the biotechnology company’s stock worth $525,000 after buying an additional 34,626 shares during the last quarter. Institutional investors and hedge funds own 33.61% of the company’s stock.

Evogene Company Profile

Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.

Further Reading: What does cost of debt say about a company’s financial health?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.